Astria Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ATXS and buy or sell other stocks, ETFs, and their options commission-free!About ATXS
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway.
CEOJill C. Milne, PhD
CEOJill C. Milne, PhD
Employees78
Employees78
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2008
Founded2008
Employees78
Employees78
ATXS Key Statistics
Market cap709.95M
Market cap709.95M
Price-Earnings ratio-5.85
Price-Earnings ratio-5.85
Dividend yield—
Dividend yield—
Average volume581.79K
Average volume581.79K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$13.29
52 Week high$13.29
52 Week low$3.56
52 Week low$3.56
Stock Snapshot
As of today, Astria Therapeutics(ATXS) shares are valued at $12.58. The company's market cap stands at 709.95M, with a P/E ratio of -5.85.
On 2026-03-12, Astria Therapeutics(ATXS) stock opened at —, reached a high of —, and a low of —.
The Astria Therapeutics(ATXS)'s current trading volume is 0, compared to an average daily volume of 581.79K.
In the last year, Astria Therapeutics(ATXS) shares hit a 52-week high of $13.29 and a 52-week low of $3.56.
In the last year, Astria Therapeutics(ATXS) shares hit a 52-week high of $13.29 and a 52-week low of $3.56.
People also own
Based on the portfolios of people who own ATXS. This list is generated using Robinhood data, and it’s not a recommendation.